Discover
CSBR
Champions Oncology, Inc.
6.04
2 x 4.38
2 x 7.78
bid
ask
-
0.12
1.87%
2 @ 04:00 PM
6.08 +0.04 (0.58%)
| Ytd | -12.52% | |
| 1y | -16.16% |
6.04
day range
6.16
5.50
52 week range
9.63
| Open | 6.16 | Prev Close | 6.16 | Low | 6.04 | High | 6.16 | Mkt Cap | 83.95M |
| Vol | 2.25K | Avg Vol | 8.37K | EPS | -0.18 | P/E | N/A | Forward P/E | 42.68 |
| Beta | 0.49 | Short Ratio | 20.86 | Inst. Own | 49.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-12 | 50-d Avg | 6.05 | 200-d Avg | 6.37 | 1yr Est | 8.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-11 | 2024-10 | 0 | 0.05 | N/A | N/A |
| 2024-09-11 | 2024-07 | 0 | 0.09 | N/A | N/A |
| 2024-07-18 | 2024-04 | 0 | -0.01 | N/A | N/A |
| 2024-03-12 | 2024-01 | 0 | -0.19 | N/A | N/A |
| 2023-12-12 | 2023-10 | -0.17 | -0.15 | 0.02 | 11.76% |
| 2023-09-13 | 2023-07 | 0 | -0.19 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-12 | Craig-Hallum | Upgrade | Buy | Buy |
| 2024-09-12 | Craig-Hallum | Upgrade | Hold | Buy |
| 2024-03-13 | Craig-Hallum | Downgrade | Buy | Hold |
| 2023-09-22 | Roth MKM | Upgrade | Buy | Buy |
| 2021-03-15 | Roth Capital | Upgrade | Buy | |
| 2019-11-18 | Benchmark | Upgrade | Speculative Buy |
Profile
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-30 | ACKERMAN JOEL | Director | 962.13K | Conversion of Exercise of derivative security |
| 2024-01-11 | MENDELSON DANIEL NEWMAN | Director | 198.63K | Purchase |
| 2023-03-16 | MORRIS RONNIE | Chief Executive Officer | 858.88K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Battery Management Corp. | 2.42M | 19.64M | 17.52% |
| 2024-09-29 | NEA Management Company, LLC | 1.71M | 13.90M | 12.40% |
| 2024-09-29 | Tocqueville Asset Management L.p. | 705.21K | 5.72M | 5.10% |
| 2024-09-29 | Vanguard Group Inc | 307.00K | 2.49M | 2.22% |
| 2024-09-29 | Renaissance Technologies, LLC | 119.99K | 973.13K | 0.87% |
| 2024-09-29 | Blackrock Inc. | 116.19K | 942.31K | 0.84% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 235.74K | 1.91M | 1.71% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 69.17K | 560.98K | 0.50% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 31.53K | 255.72K | 0.23% |
| 2024-10-30 | iShares Micro Cap ETF | 15.86K | 128.60K | 0.11% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 10.96K | 88.87K | 0.08% |
| 2024-07-30 | Schwab Capital Trust-Total Stock Market Index Fund | 6.85K | 55.59K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2015-08-12 |
| 1 : 12 | 2015-08-10 |